Protocol Ledger

NCT06212596 · Phase II · COMPLETED

Selinexor, Cyclophosphamide and Prednisone in Myeloma

Interventional Phase II clinical trial protocol NCT06212596 sponsored by University of Leeds in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2018-07-16 Enrollment: 66 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT06212596
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)66 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06212596
Protocol FieldVerified Registry Value
NCT IdentifierNCT06212596
Consolidated Lead SponsorUniversity of Leeds
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment66 participants (ACTUAL)
Registered Start Date2018-07-16
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06212596
Hospital Research SiteLocationSite Profile
Leicester Royal InfirmaryLeicester, United KingdomOpen Hospital Dossier ->
Imperial College Healthcare NHS TrustLondon, United KingdomOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI